Search

Displaying results 1151 - 1160 of 10000 in total
  1. Drug

    Vinflunine

    go.drugbank.com/drugs/DB11641
    ApprovedInvestigational

    In 2009, vinflunine was approved by the European Medicines Agency (EMA) as a second-line therapy of metastatic and advanced urothelial cancer after failure of platinum-based treatment [A32626]. … Vinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France.

  2. Drug

    Duvelisib

    go.drugbank.com/drugs/DB11952
    ApprovedInvestigational

    All the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585] … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma

  3. Drug

    Calcium acetate

    go.drugbank.com/drugs/DB00258
    Approved

    The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. … The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime.

    Mixtures: Lypholyte Multi-electrolyte Conc Inj, PERİFERAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ, 500 ML SETLİCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Trihexyphenidyl

    go.drugbank.com/drugs/DB00376
    ApprovedInvestigational

    [A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects. … [L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity.

  5. Drug

    Cupric Chloride

    go.drugbank.com/drugs/DB09131
    Approved

    Cupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

    Mixtures: Tracel Injektionslösung in einer Fertigspritze, Trace Elements Solution InjSynonyms: copper(II) chloride
  6. Drug

    Riboflavin

    go.drugbank.com/drugs/DB00140
    ApprovedInvestigationalNutraceuticalVet approved

    It occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms in tissues and cells are as flavin mononucleotide and flavin-adenine dinucleotide. … Nutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables. The richest natural source is yeast.

    Mixtures: Multi II IV Vi Tab, Vc II
  7. Drug

    Capsaicin

    go.drugbank.com/drugs/DB06774
    ApprovedInvestigational

    Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements … Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations.

    Mixtures: Tianhe Gutong Tiegao (in Polyisobutylene Carrier), Transderm-IQSynonyms: (E)-8-Methyl-N-vanillyl-6-nonenamide, trans-8-Methyl-N-vanillyl-6-nonenamide
  8. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas … [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]

  9. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to

  10. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy